Efficacy of MitraCLip Vs. PASCAL for the TrEAtment of MitraL REgurgiTation in an All-comer Population

Efficacy of Mitraclip Vs. PASCAL for the Treatment of Mitral Regurgitation in an All-comer Population

To investigate potential differences in procedural outcomes of both commercially available transcatheter edge-to-edge mitral valve repair devices in a non-selected clinical setting.

In the context of M-TEER, two different systems (MitraClip vs. PASCAL) are CE certified and clinically available. In the case of non-complex anatomy, both systems are comparable in terms of effectiveness. Whether this holds true in cases of complex or highly complex anatomy in an "Allcomer patient population" is currently unclear.

Inclusion Criteria:

• Age equal or above 18 years
• Written consent
• Heart Team recommends M-TEER

Exclusion Criteria:

• Mitral Stenosis (MV mean PG > 5 mmHg)
• Cardiogenic shock or hemodynamic instability at the time of intervention
• Active endocarditis
• Participant in another interventional cardiology study